Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles

Antimicrob Agents Chemother. 2000 Jul;44(7):2004-6. doi: 10.1128/AAC.44.7.2004-2006.2000.

Abstract

Amphotericin B is the only recognized antifungal used in the treatment of mucormycosis. In this study, we evaluated various combinations of amphotericin B, fluconazole, and trovafloxacin or ciprofloxacin in the treatment of murine pulmonary mucormycosis. The combination of fluconazole and a quinolone has a marked effect on the outcome of murine pulmonary mucormycosis. Even though we did not optimize therapy with the drugs, these experiments suggest that azoles, especially fluconazole, in combination with either trovafloxacin or ciprofloxacin were effective in the treatment of this aggressive mycosis in the mouse model.

MeSH terms

  • 4-Quinolones
  • Animals
  • Anti-Infective Agents / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Fluconazole / therapeutic use*
  • Lung Diseases, Fungal / drug therapy*
  • Lung Diseases, Fungal / mortality
  • Male
  • Mice
  • Mice, Inbred ICR
  • Mucormycosis / drug therapy*
  • Mucormycosis / mortality
  • Rhizopus / drug effects
  • Treatment Outcome

Substances

  • 4-Quinolones
  • Anti-Infective Agents
  • Antifungal Agents
  • Fluconazole